Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Lipocine (LPCN) over the last 13 years, with Q3 2025 value amounting to $1.9 million.

  • Lipocine's Total Current Liabilities rose 2212.86% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 2212.86%. This contributed to the annual value of $1.5 million for FY2024, which is 4250.95% down from last year.
  • As of Q3 2025, Lipocine's Total Current Liabilities stood at $1.9 million, which was up 2212.86% from $1.4 million recorded in Q2 2025.
  • Lipocine's Total Current Liabilities' 5-year high stood at $8.8 million during Q2 2021, with a 5-year trough of $1.3 million in Q1 2025.
  • Over the past 5 years, Lipocine's median Total Current Liabilities value was $1.8 million (recorded in 2023), while the average stood at $2.9 million.
  • In the last 5 years, Lipocine's Total Current Liabilities skyrocketed by 10814.56% in 2021 and then crashed by 8054.9% in 2022.
  • Lipocine's Total Current Liabilities (Quarter) stood at $5.6 million in 2021, then crashed by 70.12% to $1.7 million in 2022, then soared by 56.82% to $2.6 million in 2023, then tumbled by 42.51% to $1.5 million in 2024, then grew by 27.64% to $1.9 million in 2025.
  • Its last three reported values are $1.9 million in Q3 2025, $1.4 million for Q2 2025, and $1.3 million during Q1 2025.